GLIMET Tablets
Composition: GLIMET is available in two strengths: Pioglitazone 15 mg + Metformin 500 mg and Pioglitazone 15 mg + Metformin 850 mg.
Product Family: GLIMET belongs to the oral antidiabetic drug family and combines a thiazolidinedione (pioglitazone) with a biguanide (metformin) to support blood glucose management in adults with type 2 diabetes mellitus.
Product Overview: GLIMET combines two complementary antidiabetic agents. Pioglitazone improves the body's sensitivity to insulin, while metformin helps reduce glucose production in the liver and improves insulin sensitivity. This combination supports individualized diabetes management alongside a balanced diet and regular physical activity.
Indications: GLIMET is indicated for adults with type 2 diabetes mellitus when treatment with pioglitazone and metformin is considered appropriate. It is not intended for the treatment of type 1 diabetes or diabetic ketoacidosis.
Clinical Benefits: The combination of pioglitazone and metformin targets different aspects of glucose regulation. It may help improve glycemic control when prescribed appropriately, supporting a comprehensive diabetes management plan that includes lifestyle measures and regular monitoring.
Dosage and Administration: The dose should be individualized by the prescribing healthcare professional according to blood glucose control, previous treatment, kidney function, tolerability, and the selected strength. Metformin-containing tablets are generally taken with meals to help reduce gastrointestinal discomfort. Patients should not change the dose or switch between strengths without medical advice.
Directions for Use: Take GLIMET exactly as prescribed and follow the recommended meal plan, physical activity, and blood glucose monitoring schedule. Regular medical follow-up is important to assess treatment response and ongoing suitability.
Usage During Pregnancy: GLIMET should not be used during pregnancy unless specifically directed by a specialist. Diabetes management during pregnancy requires individualized treatment, and insulin is commonly preferred. Patients who are pregnant or planning pregnancy should consult their healthcare professional promptly.
Drug Interactions: Medicines that may affect blood glucose, kidney function, or fluid balance can influence the safety or effectiveness of GLIMET. Important examples include insulin and sulfonylureas, which may increase the risk of hypoglycemia when used in combination; certain diuretics; corticosteroids; and medicines that affect kidney function. Inform the prescribing healthcare professional about all medicines and supplements being used.
Product Highlights: GLIMET offers a dual-action oral treatment option for adults with type 2 diabetes who require both pioglitazone and metformin. Availability in 500 mg and 850 mg metformin strengths allows healthcare professionals to select an appropriate formulation according to individual treatment needs.
Product Summary: GLINET combines pioglitazone 15 mg with metformin 500 mg or 850 mg to support blood glucose control in adults with type 2 diabetes mellitus. Treatment should be individualized and monitored by a qualified healthcare professional.
Medical Notice: This product description is intended for informational and professional website use. Confirm the exact registered product name, available strengths, approved indications, and local prescribing information before publication.
Company: INTERMED